These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25376280)

  • 1. Emerging strategies for the management of hepatocellular carcinoma.
    Kudo M
    Dig Dis; 2014; 32(6):655-7. PubMed ID: 25376280
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of hepatocellular carcinoma in the age of liver transplantation.
    Martin AP
    Int J Surg; 2009 Aug; 7(4):324-9. PubMed ID: 19643691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?
    Yim SY; Seo YS; Jung CH; Kim TH; Lee JM; Kim ES; Keum B; Jong YK; An H; Kim JH; Yim HJ; Kim DS; Jeen YT; Yeon JE; Lee HS; Chun HJ; Byun KS; Um SH; Kim CD; Ryu HS
    Liver Int; 2016 Mar; 36(3):445-53. PubMed ID: 26352789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous ablation therapy for hepatocellular carcinomas.
    D'Agostino HB; Solinas A
    AJR Am J Roentgenol; 1995 May; 164(5):1165-7. PubMed ID: 7717225
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of HCC.
    de Lope CR; Tremosini S; Forner A; Reig M; Bruix J
    J Hepatol; 2012; 56 Suppl 1():S75-87. PubMed ID: 22300468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal management of hepatocellular carcinoma: challenges and opportunities.
    Lin CL; Kao JH
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1336-8. PubMed ID: 20659219
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiofrequency ablation combined with chemoembolization for early-stage hepatocellular carcinoma.
    Cho YK
    Radiology; 2008 Nov; 249(2):718-9; author reply 719. PubMed ID: 18936322
    [No Abstract]   [Full Text] [Related]  

  • 8. [Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival].
    Díaz-Sánchez A; Matilla A; Núñez O; Merino B; Peligros I; Rincón D; Salcedo M; Lo Iacono O; Vega Catalina M; Clemente G; Bañares R
    Gastroenterol Hepatol; 2010 Mar; 33(3):155-64. PubMed ID: 19945770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Established and emerging therapies for hepatocellular carcinoma.
    Cicinnati VR; Sotiropoulos GC; Beckebaum S
    Minerva Med; 2010 Dec; 101(6):405-18. PubMed ID: 21196900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology.
    Bargellini I; Florio F; Golfieri R; Grosso M; Lauretti DL; Cioni R
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):438-44. PubMed ID: 23719667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Diameter for Hepatocellular Carcinoma: Why Should Size Matter?
    Usta S; Kayaalp C
    J Gastrointest Cancer; 2020 Dec; 51(4):1114-1117. PubMed ID: 32851543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approach to hepatocellular carcinoma.
    Abrams P; Marsh JW
    Surg Clin North Am; 2010 Aug; 90(4):803-16. PubMed ID: 20637949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [RCT of chemoembolization plus rediofrequency ablation versus liver resection for hepatocellular carcinoma].
    Strobel O; Büchler MW
    Chirurg; 2016 Jun; 87(6):533. PubMed ID: 27251481
    [No Abstract]   [Full Text] [Related]  

  • 14. Liver tumors and loco-regional therapy.
    Vogel W
    Wien Med Wochenschr; 2013 Mar; 163(5-6):107-8. PubMed ID: 23456251
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of resection, liver transplantation and transcatheter oily chemoembolisation in the treatment of hepatocellular carcinoma.
    Jaeck D; Bronowicki JP; Boudejma K; Bachellier P; Chone L; Nisand G; Bazin C; Pflumio F; Uhl G; Wenger JJ; Boissel P; Bigard MA; Gaucher P; Vetter D; Wolf P; Doffoel M
    Wiad Lek; 1997; 50 Suppl 1 Pt 1():413-5. PubMed ID: 9383352
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemoembolization and bland embolization: a critical appraisal.
    Befeler AS
    Clin Liver Dis; 2005 May; 9(2):287-300, vii. PubMed ID: 15831274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities.
    Ho CM; Lee PH; Shau WY; Ho MC; Wu YM; Hu RH
    Surgery; 2012 May; 151(5):700-9. PubMed ID: 22284764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current therapy of hepatocellular carcinoma with special consideration of new and multimodal treatment concepts].
    Göbel T; Blondin D; Kolligs F; Bölke E; Erhardt A
    Dtsch Med Wochenschr; 2013 Jul; 138(27):1425-30. PubMed ID: 23801265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone.
    Kim JH; Won HJ; Shin YM; Kim SH; Yoon HK; Sung KB; Kim PN
    Ann Surg Oncol; 2011 Jun; 18(6):1624-9. PubMed ID: 21445671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.